pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,673 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT814Endpoints614BioPharma Dive237onclive165Fierce Biotech82BioSpace80raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: A turning point for pancreatic cancer patients
    Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • CDC says containing the spread of Ebola is top priority
    The Trump administration disregards infectious disease playbook, CEPI offers vaccine funding, and other health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Turn Therapeutics' eczema drug shows rapid response in mid-stage data
    California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of…
    Endpoints · 1mo ago↗ source
← prev
page 39 of 67
next →
21
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
    Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…
    Endpoints · 1mo ago↗ source
  • STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
    The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
    STAT · 1mo ago↗ source
  • #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroup
    CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Indiv…
    Endpoints · 1mo ago↗ source
  • Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
    Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront i…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
    CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment with t…
    Endpoints · 1mo ago↗ source
  • Opinion: The military’s medical corps has a serious recruitment problem
    Congress must incentivize more physicians (and their employers) to join the military medical corps, writes the former attending physician to Congress.
    STAT · 1mo ago↗ source
  • Opinion: Medical schools diversified. So where are all the diverse doctors?
    Why are residency programs disciplining and dismissing trainees in a system funded to train them?
    STAT · 1mo ago↗ source
  • STAT+: Executives reveal tech initiatives at Summa Health, eight months after General Catalyst acquisition
    Two years after General Catalyst said it was buying Ohio safety-net hospital Summa Health, executives shed light on how the “transformation” is going.
    STAT · 1mo ago↗ source
  • STAT+: Medicare still won’t say how much covering obesity drugs will cost
    Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
    STAT · 1mo ago↗ source
  • The hidden history of BPC-157, a favorite MAHA peptide
    A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.
    STAT · 1mo ago↗ source
  • STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes
    The arbitration process has protected patients but generated financial windfalls for some clinicians.
    STAT · 1mo ago↗ source
  • Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
    Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS-0…
    Endpoints · 1mo ago↗ source
  • STAT+: A standing ovation for RevMed, and caution for Akeso
    ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
    STAT · 1mo ago↗ source
  • Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
    Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
    STAT · 1mo ago↗ source
  • #ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that good
    CHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News. “H…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
    CHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…
    Endpoints · 1mo ago↗ source
  • STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
    Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
    STAT · 1mo ago↗ source
  • STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
    A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
    STAT · 1mo ago↗ source
  • STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
    By doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
    STAT · 1mo ago↗ source
  • #ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
    Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-F…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say
    CHICAGO — Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved ...
    Endpoints · 1mo ago↗ source
  • STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
    ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
    STAT · 2mo ago↗ source